InVivo Therapeutics to Hold Inaugural Langer Summit on Neurotrauma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the inaugural Langer Summit on Neurotrauma being held in North Falmouth, MA from July 6 8, 2012. The Summit is being chaired by InVivo Therapeutics co-founder Robert S. Langer, ScD, the David H. Koch Institute Professor at Massachusetts Institute of Technology.

The meeting will bring together researchers from across the world to address the challenges faced by interventions being developed for spinal cord injury and other neurological conditions. Participants will discuss the options to move recent innovations like InVivos scaffold technology and delivery systems into the clinic.

This first summit is an exciting opportunity for our scientists to interact with other researchers focused on spinal cord injury and related disorders, said InVivo Medical Director, Jonathan Slotkin, MD. We look forward to not only sharing thoughts and breakthroughs related to our first product for SCI with leaders in our industry, but also to further developing our hydrogel treatment for back and leg painfor which we recently engaged the FDA. To our knowledge, this is the first summit of its kind devoted to furthering the use of biomaterial scaffold technology for nervous system injury, cancer, and chronic pain.

The summit will also be used as a platform to establish an annual grant that will be given by InVivo to inventors developing new treatments for the neurotrauma industry. The award will serve to stimulate innovation and cutting-edge ideas in the fields of neuroprotection and regeneration.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Companys ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companys products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Companys business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Link:
InVivo Therapeutics to Hold Inaugural Langer Summit on Neurotrauma